CD20

Laboratory assay overview

To aid in the diagnosis of chronic lymphocytic leukemia or lymphoma. Initial markers evaluated: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD38, CD56, CD64, FMC7, sKappa, sLambda. CD45 is used for gating.

Laboratory assay overview

To aid in the follow-up diagnosis of chronic lymphocytic leukemia or lymphoma. Initial markers evaluated: CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD38, HLA-Dr, sKappa, sLambda. CD45 is used for gating.

Laboratory assay overview

To aid in the follow up of a known hairy cell leukemia. Initial markers evaluated: CD11C, CD19, CD20, CD22, CD25, CD103, sKappa, sLambda. CD45 is used for gating.

Laboratory assay overview

This panel may be used in the initial evaluation of patients with clinical suspicion of hematologic neoplasms. Immunophenotyping by flow cytometry can aid in the diagnosis and classification of leukemia and lymphoma [1]. Subsequent testing of additional cell surface antigens may be needed to help establish a diagnosis. Leukemias and lymphomas are heterogenous morphologically and clinically. Identification of cell surface markers (T cell, B cell, progenitor, and myeloid markers) by flow cytometry can help assign a cell lineage to neoplastic cells. Accurate immunotyping aids in the diagnosis, classification, and prognosis of hematologic neoplasm and may inform treatment decisions [1]. This immunotyping panel is designed to expedite the evaluation of patients without provisional diagnosis of a certain type of hematologic neoplasm. The results of this panel must be interpreted with cytological, histological, genetic, and clinical findings to generate accurate diagnosis. Additional cell surface markers not included in this panel may be needed to evaluate certain hematologic malignancies (eg, hairy cell leukemia). Because non-viable cells lead to non-specific antibody binding, specimens should be processed as early as possible. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. Reference 1. Bain BJ, et al. Leukaemia Diagnosis. 5th ed. John Wiley & Sons;2017:69-134.

Laboratory assay overview

Next-generation flow cytometry (NGFC) is an ultra-sensitive tool for assessing measurable residual disease (MRD) in hematologic malignancies. MRD tests provide crucial prognostic information to clinicians, helping them evaluate treatment response and determine if a patient is in stable remission or relapse.

Laboratory assay overview

Thyroid masses are evaluated by fine needle aspiration (FNA). This assay will provide cytologic evaluation and diagnosis of thyroid FNAs by a cytopathologist.

Laboratory assay overview

This assay provides morphologic review along with appropriate molecular testing for diagnosis of thyroid samples obtained by fine needle aspirate (FNA). Any molecular testing required will be reflexed based on cytologic findings and a comprehensive assessment issued summarizing the overall findings. Papillary thyroid cancer (PTC) is associated with BRAF V600E mutation (40-50% of cases) and RET overexpression through juxtaposition to the PTC genes by chromosome fusion (5-40% of cases). Follicular thyroid carcinomas are specifically associated with PPARG-PAX8 gene fusions in 25-50% of cases. NRAS, HRAS and KRAS mutations are more commonly associated with follicular thyroid neoplasms than PTC.